July 22, 2019
Takashi Shimamoto, Head of Oncology Science Unit, MSD K.K. at 2019 JSMO Annual Meeting US Merck’s anti-PD-1 antibody Keytruda (pembrolizumab) faced an unexpected setback in liver cancer as its global PIII study failed to hit its goal earlier this year,...read more